Plain-English translation of NCT06890598 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Carcinoma, Non-Small-Cell Lung research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a new targeted cancer drug, works better when combined with immunotherapy medicines ( or ) compared to immunotherapy alone in people with non-small cell lung cancer that has a specific genetic mutation called KRAS G12C. The trial is split into two parts: one for people who have had surgery to remove their tumor, and another for people whose tumors cannot be surgically removed.
Currently, people with this specific type of lung cancer have limited treatment options. Researchers believe that combining this new targeted medication with existing immunotherapy drugs may help the body's immune system fight cancer more effectively and improve survival.
You likely qualify if…
You likely don't qualify if…
You would take the study medication by mouth daily and receive intravenous infusions of immunotherapy every few weeks for up to one year, then continue the oral medication alone for up to two more years. The study involves regular clinic visits for blood tests, imaging scans, and health monitoring. The entire commitment could last up to three years, though some participants may be followed for shorter periods depending on how their cancer responds.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States